IRB Number:

1397-05

Trial Status:

Open for Enrollment

Phase: II

Why is this study being done?

This research study is being done to see if patients who are treated with this drug combination will go into remission (a complete or partial disappearance of the disease), and if the remission will be maintained with CAMPATH-1H treatment.

Who is Eligible to Participate in the Study?

Men or women 18 years of age and older diagnosed with chronic lymphocytic leukemia may be eligible to participate in this research study.

What is Involved With this Study?

If you take part in this study, you will be given the following drugs: rituximab, pentostatin, and cyclophosphamide. You will be given all these medicines for six cycles. One cycle is 21 days. You will then be checked to see how your disease has responded to the treatment. For the first cycle, rituximab will be given to you three times on the first week only. For the second, third, fourth, fifth, and sixth cycles, you will get rituximab once on the first week of each cycle only. If the drugs had a major effect against the disease (almost complete clearance of detectable disease), you will get CAMPATH-1H for four weeks. But, if the disease does not respond to treatment then you will get CAMPATH-1H for eighteen weeks.

How long will the Study run?

Participants will be enrolled in this research study for up to five years with treatment and follow up.

Who can I Contact for Additional Information on this Trial?

Complete Request Form for Cancer Clinical Trial Information at Mayo Clinic or
For more information about this study or other clinical trial options, please contact our Mayo Clinic Cancer Center Clinical Trials Referral Office.

• Patients living within the United States, call 507-538-7623, or e-mail cancerclinicaltrials@mayo.edu


• Patients living outside the United States may call our International Office at 507-284-8884, or e-mail intl.mcr@mayo.edu.

What is/are the Locations of this Clinical Trial?

• Rochester, MN

Last updated: 07/10/2009